Schizophrenia spectrum and other psychotic disorders

TY - JOUR

T1 - Schizophrenia spectrum and other psychotic disorders

AU - Pagsberg, Anne Katrine

PY - 2013/2

Y1 - 2013/2

N2 - The DSM-5 list of diagnoses concerning schizophrenia spectrum and other psychotic disorders is expected to be revised and graduated from mild to severe. The proposed changes for the diagnosis of schizophrenia affect demands for characteristic symptoms, clarify relation to pervasive developmental disorders, and eliminate the classic subtypes of schizophrenia. A dimensional assessment will be measured on a 0-4 point scale. It is recommended that the concept of attenuated psychosis syndrome is further investigated. The propositions affecting characteristic symptoms of schizophrenia might increase diagnostic reliability and validity, but it is estimated to exclude about 2 % of patients currently diagnosed with DSM-IV schizophrenia from fulfilling criteria for DSM-5 schizophrenia. It might generate a problem for future young patients if the changes concerning demands on characteristic symptoms turn out to be more restrictive, leaving out a percentage of patients with psychotic symptoms from a diagnosis of schizophrenia; which in practice opens possibilities for intensive treatment options. On the other hand, not including attenuated psychosis syndrome at the present might protect patients from stigmatization and pharmacological treatment on poor indication. The introduction of dimensional assessments may make schizophrenia subtyping redundant and has the potential to enrich clinical practice and bridge communication between child and adolescent and adult psychiatry. The most recent guidelines for assessment and treatment of children and adolescents with schizophrenia are from 2001. They provide differentiated recommendations regarding diagnostics, assessment of symptoms and functioning and treatment strategies. There is an urgent need for updated guidelines in this field, especially concerning specific treatment guidelines.

AB - The DSM-5 list of diagnoses concerning schizophrenia spectrum and other psychotic disorders is expected to be revised and graduated from mild to severe. The proposed changes for the diagnosis of schizophrenia affect demands for characteristic symptoms, clarify relation to pervasive developmental disorders, and eliminate the classic subtypes of schizophrenia. A dimensional assessment will be measured on a 0-4 point scale. It is recommended that the concept of attenuated psychosis syndrome is further investigated. The propositions affecting characteristic symptoms of schizophrenia might increase diagnostic reliability and validity, but it is estimated to exclude about 2 % of patients currently diagnosed with DSM-IV schizophrenia from fulfilling criteria for DSM-5 schizophrenia. It might generate a problem for future young patients if the changes concerning demands on characteristic symptoms turn out to be more restrictive, leaving out a percentage of patients with psychotic symptoms from a diagnosis of schizophrenia; which in practice opens possibilities for intensive treatment options. On the other hand, not including attenuated psychosis syndrome at the present might protect patients from stigmatization and pharmacological treatment on poor indication. The introduction of dimensional assessments may make schizophrenia subtyping redundant and has the potential to enrich clinical practice and bridge communication between child and adolescent and adult psychiatry. The most recent guidelines for assessment and treatment of children and adolescents with schizophrenia are from 2001. They provide differentiated recommendations regarding diagnostics, assessment of symptoms and functioning and treatment strategies. There is an urgent need for updated guidelines in this field, especially concerning specific treatment guidelines.

U2 - 10.1007/s00787-012-0354-x

DO - 10.1007/s00787-012-0354-x

M3 - Review

C2 - 23202885

SN - 1433-5719

VL - 22

SP - S3-9

JO - European Child and Adolescent Psychiatry, Supplement

JF - European Child and Adolescent Psychiatry, Supplement

IS - 1 Suppl

ER -